Group 1 - The core product, Darilresib, launched by the company, has seen a significant increase in search volume, with over 160% growth in the past two weeks, making it a popular choice in the insomnia treatment market [1] - The drug addresses a pressing issue, as nearly 48.5% of adults in China experience sleep-related problems, according to the 2025 China Sleep Health Survey Report [1] - Darilresib operates as a dual appetite receptor antagonist, improving nighttime sleep quality and daytime functionality without altering sleep structure, and is not classified as a controlled substance, lowering the barrier for patient access [1] Group 2 - The company has streamlined its drug launch process, reducing the time from 8 months to just over 2 months, achieving an efficiency improvement of over 60% by directly importing the drug and completing packaging at its Hainan production base [1] - The collaboration with Meituan Buy Medicine has led to a deep partnership for the drug's launch, facilitating rapid distribution across multiple cities in China [1][2] - The product is available in two formats, 7 tablets and 20 tablets, to meet diverse patient needs, with plans to cover over 100 cities and thousands of 24-hour pharmacies [2]